<DOC>
	<DOC>NCT00292838</DOC>
	<brief_summary>To investigate the validity of a clinical model to determine the relative potency of different preparations of inhaled corticosteroids used for the treatment of asthma or of eosinophilic bronchitis without asthma.</brief_summary>
	<brief_title>Relative Potency of Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Sputum eosinophilia &gt;3% Adults age 1870 years History of episodic wheeze, chest tightness, dyspnea or cough within the last 12 months. FEV1 ≥ 60% predicted Steroid naive or on not more than 500 µg a day of beclomethasone or equivalent. Able to give written informed consent 1. Recent asthma or COPD exacerbation (as judged by the clinician) due to respiratory infection within the last month 2. Relevant seasonal allergen exposure within 4 weeks or within the course of the study 3. Treatment with prednisone or antibiotics or hospitalisation within the past 6 weeks 4. Other respiratory diseases 5. Women who are pregnant or unwilling to use appropriate contraception during the study 6. Unable to withhold shortacting ßagonist treatment for 6 hours before visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Eosinophilic bronchitis with asthma</keyword>
	<keyword>Eosinophilic bronchitis without asthma</keyword>
</DOC>